Friday, 17 October 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 17 October 2025
News

Aussie manufacturing deal struck

Posted 16 October 2025 PM

A strategic supplier relationship between Aussie cell therapy company Chimeric Therapeutics and the Viral Vector Manufacturing Facility (VVMF) has been hailed as a win for local advanced therapy capabilities.

Under a freshly inked Letter Of Intent, VVMF will support process development, technology transfer, and GMP manufacturing of Lentiviral vectors for Chimeric’s clinical stage chimeric antigen receptor (CAR-T) program. Viral vectors are a critical component in the production of CAR-T therapies, which are transforming cancer treatment globally.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (22)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.